EFEMP1 has been previously shown to suppress the epithelial-mesenchymal transition in endometrial carcinoma through Wnt/β-catenin signaling, for which WNT2B is an activator (Blomfield et al., 2023; Yang et al., 2016). Here, WNT2B is linked to endometrial carcinoma.